| Host: |
HEK293 |
| Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-2019 nCoV/COVID19 Spike protein S1-His-AVI protein was developed from hek293 and has a target region of His-AVI. For use in research applications. |
| Conjugation: |
Unconjugated |
| Formulation: |
Lyophilised from 0.2 µm filtered PBS solution pH7.4. |
| Dilution Range: |
Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers. |
| Storage Instruction: |
The lyophilized protein is stable for at least 1 year from date of receipt at-20°C. NA |
| Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Immunoreactivity: |
The activity was tested by binding Human ACE2-Fc in functional ELISA assay, the calculated EC50 was determined to be 0.1ug/ml. NA |
| Immunogen Region: |
ECD |
| Immunogen: |
DNA sequence encoding extracellular fragment[16-675] of NCOV Spike S1 [accession# QIC53204.1] including a C terminal polyHis Avi tag was expressed in HEK cells. NA |
| Background | Recombinant NCOV S1 encodes the NCOV spike glycoprotein S1 sequence. This molecule has a calculated mass of approximately 76kDa. Recombinant S1 migrates due to glycosylation as an approximately 120 kDa protein under reducing conditions in SDS-PAGE. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
